{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Esther CR"],"funding":["COPD Foundation","NIDDK NIH HHS","NIAID NIH HHS","NIEHS NIH HHS","NHLBI NIH HHS","Foundation for the National Institutes of Health","National Heart, Lung, and Blood Institute","National Institutes of Health","Alpha-1 Foundation"],"pagination":["1239-1249"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9131049"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["161(5)"],"pubmed_abstract":["<h4>Background</h4>Improved understanding of the pathways associated with airway pathophysiologic features in COPD will identify new predictive biomarkers and novel therapeutic targets.<h4>Research question</h4>Which physiologic pathways are altered in the airways of patients with COPD and will predict exacerbations?<h4>Study design and methods</h4>We applied a mass spectrometric panel of metabolomic biomarkers related to mucus hydration and inflammation to sputa from the multicenter Subpopulations and Intermediate Outcome Measures in COPD Study. Biomarkers elevated in sputa from patients with COPD were evaluated for relationships to measures of COPD disease severity and their ability to predict future exacerbations.<h4>Results</h4>Sputum supernatants from 980 patients were analyzed: 77 he"],"journal":["Chest"],"pubmed_title":["Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD."],"pmcid":["PMC9131049"],"funding_grant_id":["R01 AI129958","UH3 HL123645","HHSN268200900015C","R01 HL136961","HHSN268200900017C","P30-DK065988","R01-HL136961","HHSN268200900019C","P50-HL107168","P30-ES10126","P01-HL110873","R01 HL148215","HHSN268200900013C","P01 HL108808","P30 DK065988","P01 HL110873","P01-HL108808","U01 HL137880","HHSN268200900016C","P30 ES010126","HHSN268200900018C","U24 HL141762","UH3-HL123645","P50 HL107168","HHSN268200900020C","HHSN268200900014C"],"pubmed_authors":["Krishnan JA","Tesfaigzi Y","Anderson WH","Hansel NN","Kleerup EC","Oelsner EC","Galban C","Labaki WW","Bhatt SP","Bowler RP","Putcha N","Alexis NE","Kesimer M","Comellas AP","Christenson SA","Paulin L","Doerschuk CM","Cooper CB","Newell JD","Pirozzi C","Lazarus SC","Woodruff PG","Subpopulations and Intermediate Outcome Measures in COPD Study","Wells JM","Couper DJ","Freeman CM","Tashkin DP","Arjomandi M","Paulin LM","Barr RG","O'Neal WK","Han MK","Bateman LA","Paine R","Criner GJ","Kanner RE","Huang YJ","Hoffman EA","LaVange LM","Hastie AT","Boucher RC","Martinez FJ","Moore WC","Curtis JL","Bleecker ER","Wise RA","Esther CR","Ortega VE","Meyers DA","Raman S","Huang Y","Peters SP","Kim V","Barjaktarevic I","Crystal RG","Dransfield MT","Rennard SI","Drummond B","Ceppe A","Kaner RJ"],"additional_accession":[]},"is_claimable":false,"name":"Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD.","description":"<h4>Background</h4>Improved understanding of the pathways associated with airway pathophysiologic features in COPD will identify new predictive biomarkers and novel therapeutic targets.<h4>Research question</h4>Which physiologic pathways are altered in the airways of patients with COPD and will predict exacerbations?<h4>Study design and methods</h4>We applied a mass spectrometric panel of metabolomic biomarkers related to mucus hydration and inflammation to sputa from the multicenter Subpopulations and Intermediate Outcome Measures in COPD Study. Biomarkers elevated in sputa from patients with COPD were evaluated for relationships to measures of COPD disease severity and their ability to predict future exacerbations.<h4>Results</h4>Sputum supernatants from 980 patients were analyzed: 77 he","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-05-09T22:38:07.795Z","creation":"2025-02-19T03:26:19.402Z"},"accession":"S-EPMC9131049","cross_references":{"pubmed":["34801592"],"doi":["10.1016/j.chest.2021.10.049"]}}